Cancer Research

The tumour microenvironment
#Aston University #Cancer research #Theranostics

UK university awarded €1.2m for cancer ‘magnetobots’ project 

Aston University has been awarded €1.2 million to fund an international project developing cancer tumour-fighting ‘magnetobots’.  The university was awarded the funding through the Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges programme for the project bringing together 18 partner organisations.  The magnetobots, made from microorganisms called magnetotactic bacteria, will combine theranostic technologies to… Read More

#Cancer Research #News

Lung cancer
#Gene mutation #Genetic profiling #Japan #Lung cancer

Genetic mutations could be therapeutic target in lung cancer 

Researchers have uncovered the genetic basis of multiple primary lung cancers, shedding light on potential therapeutic targets for treatment.  A team of researchers, led by Professor Motoshi Suzuki from the Department of Molecular Oncology, Fujita Health University, Japan, along with graduate student Dat Quoc Tran from the university, distinguished… Read More

#Cancer Research #News

CAR-T therapy
#Blood cancer #CAR T-cell therapy #University College London #University of Oxford

CAR T-cell therapy selectively targets cancer mutations 

A new CAR T-cell therapy can target key mutations causing rare blood cancers and leave healthy blood cells unharmed, scientists say.  A research effort led by University College London (UCL) and the University of Oxford engineered a CAR T-cell therapy which can reprogramme a patient’s own immune cells… Read More

#Cancer Research #News

Patients receiving chemotherapy
#Nuclear medicine #Theranostics #University of Queensland

Patients denied personalised cancer care, study says 

Cancer patients are being denied access to a “game changer” method of treatment, a new study warns.  Health economists Dr Yufan Wang and Professor Haitham Tuffaha led a review into the value of theranostic nuclear medicine, an innovative frontier in cancer treatment, and concluded patients are being… Read More

#Cancer Research #News

Patient having a mammogram
#Breast cancer #HER2

Breast cancer patients profiled to determine drug efficacy  

Researchers have identified which breast cancer patients should be treated with anthracyclines and who can safely avoid side effects of the drugs, a study shows.  Scientists from precision oncology company Agendia published a paper in JCO Precision Oncology, which demonstrates HER2-negative (HR+HER2-) early-stage breast cancer (EBC) patients are most… Read More

#Cancer Research #News

Ageing hands
#Bowel cancer #Cancer Grand Challenges #Gastrointestinal cancer #Lung cancer

Faster ageing could be linked to developing cancer 

People who show signs of faster biological ageing could be more likely to develop cancer earlier in life, a new study suggests.  Scientists from the PROSPECT team, funded by Cancer Grand Challenges, analysed blood samples and health information from more than 164,000 people from the UK and… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #Lonza

Lonza and InduPro to collaborate on next-gen ADC therapies 

Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies.  Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology antigens, supporting the… Read More

#Business & Investment #Cancer Research #News

Bladder cancer
#Bladder cancer #Oncology #University of Edinburgh #Xiamen University

Algae microbots increase drug penetration 10x in bladder cancer

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumours, researchers say.   Tracked using real-time imaging, the miniature robots help drugs penetrate deep into tumour tissue while limiting damage to healthy cells.   In lab tests with… Read More

#Cancer Research #Editor's Choice #News

#Elicio Therapeutics #KRAS #Oncology #Pancreatic cancer #Phase II trial

Elicio refines its Phase III strategy for ELI-002 7P in pancreatic cancer

Elicio Therapeutics has reported that its Phase II AMPLIFY-7P study evaluating ELI-002 7P in patients with adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC) did not meet its endpoint of disease-free survival (DFS).   However, the company says landmark analyses during active ELI-002 7P treatment indicated early treatment benefit. Post-hoc… Read More

#Cancer Research #News

Ovarian cancer cells
#Clinical trial #Immunology / Virology & Vaccines #Mayo Clinic #Ovarian cancer

Ovarian cancer vaccine with 40% survival rate to be advanced 

A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates.  Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study compared to the… Read More

#Business & Investment #Cancer Research #News

Myeloma
#Clinical trial #Combination therapy #Myeloma

Therapy enables 89% survival rate in myeloma patients 

A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma.  Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival… Read More

#Cancer Research #News

Bile duct
#ASCO #Incyte #Oncology #Phase III trial

A potentially practice-changing advance in bile duct cancer

Results presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase III FIGHT-302 trial showed that Incyte’s pemigatinib (Pemazyre), significantly improved progression-free survival in the first-line setting in cholangiocarcinoma (bile duct cancer).  The drug was compared with gemcitabine and cisplatin, a long-standing… Read More

#Cancer Research #Editor's Choice #News

MRI showing glioblastoma
#Brain cancer #Clinical trial #PhoreMost

PhoreMost advances brain cancer programme to trial  

PhoreMost has announced a treatment for brain cancers as its lead programme, also appointing Dr Gabriel Fox as Chief Medical Officer.  The biotechnology company will progress PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers, towards Phase I clinical trial.  PMC-001 is… Read More

#Cancer Research #News

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News